SB 1094 creates a controlled framework allowing pharmacists to substitute a prescribed biological product only with a biosimilar or FDA-designated interchangeable product, subject to prescriber instructions and a patient-cost requirement. The bill mandates notification to the prescriber about the exact product dispensed within five days and assigns responsibility for substitution decisions to the dispensing pharmacist.
This matters for pharmacists, prescribers, payers (including Medi‑Cal), and health IT vendors because it changes who decides substitution, requires new documentation and notification workflows, and ties substitution to patient out-of-pocket cost rather than list price or formulary alone. It also clarifies liability: prescribers are insulated from pharmacists’ substitution choices, but pharmacists assume the responsibilities of the substituting act.
At a Glance
What It Does
Permits pharmacists to substitute only biosimilar or FDA‑interchangeable biological products when the prescriber has not personally indicated “Do not substitute,” requires the dispensing pharmacist (or designee) to record the exact product and manufacturer within five days in an electronic system or by other means, and conditions substitution on equal-or-lower patient cost. It also shifts substitution liability to the pharmacist and requires patient notification of any substitution.
Who It Affects
Community and institutional pharmacists, pharmacies that dispense biologics, prescribers who order biologic drugs, Medi‑Cal and other payers, pharmacy benefit managers, and electronic health record/e-prescribing vendors that must support the mandated entries and exchanges.
Why It Matters
The bill standardizes substitution practice for biologics in California, strengthens traceability by forcing timely product identification, and creates operational and legal obligations for pharmacists and records systems—potentially lowering patient costs but increasing compliance and documentation burdens for dispensers and IT systems.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 1094 restricts pharmacist-initiated substitution of biological medicines to products that are either biosimilars or formally determined by the FDA to be interchangeable. A pharmacist may not substitute if the prescriber personally indicates “Do not substitute” in the ways the bill specifies.
For traditional paper prescriptions the bill emphasizes a handwritten or orally-stated prohibition by the prescriber; for electronic prescriptions the bill allows equivalent electronic indications without requiring a manual initial.
When a pharmacist dispenses a biologic—whether the original product or a substituted biosimilar—the pharmacist or a designated staff member must record the exact product name and manufacturer within five days. That record must be placed in a system the prescriber can access (interoperable EHR, e-prescribing platform, PBM system, or pharmacy record); if those channels aren’t available, the pharmacist must notify the prescriber by fax, phone, or other prevailing means.
The bill treats an entry in one of the specified electronic systems as presumptive notice to the prescriber.SB 1094 places the decision to substitute within the pharmacist’s discretion but burdens the pharmacist with the same responsibilities they would have if they had filled a prescription written by name for the substituted product. The bill explicitly removes prescriber liability for a pharmacist’s selection or dispensing errors.
It also bars substitution when the chosen product would cost the patient more than the prescribed biological product—where “cost” expressly includes any pharmacist professional fee.The statute applies broadly, including prescriptions presented by or on behalf of people covered by federal programs or Medi‑Cal. It requires that patients be told when a substitution occurs, directs the state licensing board to post a link to the FDA’s current list of interchangeables, and preserves common payer controls—plans and insurers can still require prior authorization or other utilization controls.
Standard statutory definitions align the bill’s terms to the federal Public Health Service Act and the Food, Drug, and Cosmetic Act where those terms are used.
The Five Things You Need to Know
Pharmacists may only substitute when the alternative is a biosimilar or FDA‑designated interchangeable biological product.
The dispensing pharmacist or designee must record the exact product name and manufacturer within five days in an EHR/e‑prescribing/PBM/pharmacy record accessible to the prescriber.
A prescriber’s oral or handwritten “Do not substitute” blocks substitution; for e‑prescriptions an electronic “Do not substitute” or checked box is sufficient without manual initials.
Pharmacists assume the same responsibilities for substituted products that they would have if the product had been prescribed by name, and prescribers bear no liability for the pharmacist’s substitution acts or omissions.
A pharmacist cannot substitute if the alternative would cost the patient more than the prescribed product; “cost” includes any professional fee the pharmacist charges.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Substitution eligibility — only biosimilars or FDA‑interchangeables
This paragraph sets the gate: a pharmacist may select an alternative biological product only if the substitute is a biosimilar or an FDA‑determined interchangeable product. Practically, that ties state substitution rules directly to federal regulatory determinations and limits pharmacists from substituting on the basis of formulary preference or price alone unless the product fits those categories.
Five‑day product identification and prescriber notice presumption
These clauses require the dispenser to enter the exact product name and manufacturer within five days and list specific electronic systems that satisfy the requirement (interoperable EHRs, e‑prescribing tech, PBM systems, or pharmacy records). The statute creates a legal presumption that such an electronic entry constitutes notice to the prescriber, which matters for adverse‑event followup, reconciliation, and continuity of care.
Fallback communications when electronic access is unavailable
If the pharmacy cannot access any of the specified electronic systems, the pharmacist or designee must notify the prescriber by fax, phone, electronic transmission, or other prevailing means, with two express exceptions: when no biosimilar/interchangeable exists or when a refill is unchanged from the prior dispensing. This keeps the notification obligation practical while still prioritizing prescriber awareness.
How prescribers block substitution (handwriting, oral, and e‑prescribing rules)
The bill requires that a prescriber personally indicate “Do not substitute” to block substitution: either orally, in the prescriber’s own handwriting, or by personally initialing a checked box on a paper prescription. For electronic prescriptions, a prescriber may include the prohibition in the transmitted data or check a box without a separate manual initial. This distinction balances fraud prevention on paper with the realities of electronic workflows.
Pharmacist discretion, liability allocation, and patient‑cost condition
Substitution remains a pharmacist decision, but the pharmacist must bear the same responsibility they would have if the substituted product had been prescribed by name. The bill absolves prescribers from liability for pharmacist substitution acts or omissions. It also forbids substitutions that would raise the patient’s out‑of‑pocket cost compared to the prescribed product, explicitly counting any pharmacist professional fee in that calculation—an operational trigger that will require pharmacies to compare patient costs before substituting.
Scope, patient notice, board link, definitions, and carve‑outs
The statute applies to all prescriptions, including those for patients on federal programs and Medi‑Cal, mandates patient notification when a substitution occurs, and instructs the board to link to the FDA’s current list of interchangeables on its website. It also adopts federal definitions for terms like “biological product” and “biosimilar,” exempts immunizations, and preserves insurers’ ability to require prior authorization or other utilization controls.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients paying out‑of‑pocket — increased chance of receiving lower‑cost biosimilars when clinically appropriate, with the added protection that substitutions cannot raise their immediate cost.
- Medi‑Cal and other payers — clearer substitution rules and mandated product identification improve formulary management, claims accuracy, and pharmacovigilance for beneficiaries.
- Prescribers — the notification presumption and product recording improve drug traceability and clinical records, while the statutory protection from liability for pharmacist substitutions reduces malpractice exposure.
Who Bears the Cost
- Dispensing pharmacists and pharmacies — must adopt workflows and documentation practices (or update systems) to record product and manufacturer within five days, run patient‑cost checks before substitution, and handle extra communications and potential liability tied to substitution decisions.
- Electronic health record, e‑prescribing, and PBM vendors — required to support the specified entries and interoperability expectations; smaller vendors may need upgrades to meet the bill’s documentary pathways.
- Reference biologic manufacturers — face increased competition as substitution to biosimilars/interchangeables becomes administratively clearer, potentially reducing market share and pricing leverage.
- Payers and PBMs — while they may benefit from lower unit costs, they must manage prior authorization practices and formularies to align with state substitution rules and documentation requirements.
Key Issues
The Core Tension
The bill’s central tension is between increasing access to lower‑cost biosimilars and maintaining clinical continuity and traceability: it empowers pharmacists to lower patient costs and standardizes notification, but shifting decisionmaking and legal responsibility away from prescribers risks fragmented care, added pharmacist liability, and tracing gaps if electronic notifications don’t translate into timely prescriber awareness.
SB 1094 solves several practical problems—clarifying when substitution is permitted and forcing product identification—but it also creates implementation and policy frictions. Requiring a five‑day electronic entry presumes pharmacies and prescribers share interoperable systems or that pharmacies can reliably access PBM or EHR portals; smaller or independent pharmacies may face substantive IT and staffing costs to comply.
The law’s presumption that an electronic entry provides notice to the prescriber is administratively efficient but may not align with clinician workflows, creating a gap between legal notice and actual clinical awareness when adverse events or dosing questions arise.
The bill ties substitution to the patient’s out‑of‑pocket cost and includes pharmacist professional fees in that calculation. That protects patients from unexpected higher costs but creates ambiguity about which fees to include and when cost comparisons occur—at point of sale, at adjudication, or after benefits processing.
The shift of legal responsibility onto pharmacists clarifies prescriber exposure but raises insurer and pharmacist liability concerns; pharmacists now must weigh clinical appropriateness, cost calculations, and documentation risk with each substitution. Finally, although the statute defers to FDA determinations of interchangeability, it preserves payer prior authorization rights, which means state substitution authority could be overtaken in practice by coverage rules and utilization management.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.